

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

February 07, 2014

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Kind Attn.: Mr. K. K. Mishra

Dear Sir

Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the news papers in the matter of unaudited financial results for the quarter/nine months ended on December 31, 2013 the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila Net Profit up by 82% in Q3

Ahmedabad, February 7, 2014

For the third quarter ended 31st December 2013, Cadila Healthcare Limited registered a Net Profit of Rs. 186 crores, up by 82% from Rs. 102 crores in the corresponding period last year. The company registered a Total Income of Rs. 1,872 crores up by 17% from Rs. 1,604 crores in the corresponding period last year, on a consolidated basis.

During the quarter, the company's business in the US registered a growth of 61% and Emerging Markets business grew by 30%.

During the quarter, the company filed 31 additional ANDAs with the US FDA taking the cumulative ANDA filings for the period April-December 2013, to 49. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to 6 and filed 8 dossiers with the Mexican regulatory authority, taking the cumulative filings to 36. The company filed 9 dossiers with the ANVISA, taking the cumulative filings to 113. In the European market, the company received the approval for 15 new product dossiers and launched 2 new products in France and 3 new products in Spain. 7 new products were launched in the different Emerging Markets during the quarter.

During the quarter, the company received the US FDA approval for initiating Phase I clinical trials of ZYDPLA1 – a novel, next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes.

For Biosimilars, the company initiated Phase III clinical trials for one of the mAbs and completed Phase I clinical trials completed for both the novel biologics, PEGEPO and Rabimabs.
